论文部分内容阅读
为了观察多西紫杉醇联合表柔比星加顺铂(DDP)方案(DEP)治疗晚期胃癌的临床疗效和毒副反应,对入组的34例晚期胃癌患者给予表柔比星50 mg/m2,d1,多西紫杉醇75 mg/m2,d2,DDP 25 mg/m2,d3~d53周方案全身化疗。34例患者中完全缓解(CR)5例(14.71%),部分缓解(PR)15例(44.12%),稳定(SD)6例(17.65%),进展(PD)8例(23.53%),总有效率(CR+PR)为58.82%(20/34),疾病控制率(CR+PR+SD)为76.47%(26/34)。毒副反应主要为骨髓抑制,发生率为94.12%(32/34),其中Ⅲ、Ⅳ级占29.41%,无治疗相关性死亡。初步研究结果提示,PEP方案治疗晚期胃癌疗效肯定,虽然骨髓抑制等不良反应偏高,但有一定的治疗优势,值得进一步在临床中推广应用。
To observe the clinical efficacy and side effects of docetaxel combined with epirubicin plus cisplatin (DDP) in the treatment of advanced gastric cancer, 34 patients with advanced gastric cancer were enrolled in this study. Epirubicin 50 mg / m2, d1 , Docetaxel 75 mg / m2, d2, DDP 25 mg / m2, d3 ~ d53 weeks of systemic chemotherapy. Among the 34 patients, 5 cases (14.71%) had complete remission (CR), 15 cases (44.12%) had partial remission (PR), 6 cases (17.65%) had stable (SD) and 8 cases (23.53% The total effective rate (CR + PR) was 58.82% (20/34) and the disease control rate (CR + PR + SD) was 76.47% (26/34). The main side effects were myelosuppression, with a rate of 94.12% (32/34), of which grade Ⅲ and Ⅳ accounted for 29.41%. No treatment-related death occurred. Preliminary results suggest that, PEP regimen for the treatment of advanced gastric cancer affirmation, although the higher adverse reactions such as bone marrow suppression, but it has a certain therapeutic advantage, it is worth further promotion in clinical application.